Loading...
Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non‐small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fus...
Saved in:
| Published in: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6172052/ https://ncbi.nlm.nih.gov/pubmed/30053332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13752 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|